$BCAB

BioAtla, Inc. (BCAB) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (b) Dr. Sievers’ Resignation and Consulting Agreement On September 25, 2026, Dr. Eric Sievers resigned from his position as

BioAtla, Inc. (BCAB) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. 8-K false 0001826892 NASDAQ 0001826892 2026-07-16 2026-07-16 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): Ju

BioAtla, Inc. announced a 50-for-1 share consolidation of its common stock to increase its per-share trading price and regain compliance with Nasdaq's $1.00 minimum bid price requirement. This strategic move, effective April 6, 2026, aims to maintain the company's Nasdaq listing, which is crucial for accessing capital markets and funding ongoing research and development. Stockholders approved the consolidation on March 23, 2026, with fractional shares to be paid in cash.

BioAtla (NASDAQ: BCAB) stockholders have approved an internal merger with its wholly-owned subsidiary, BA Merger Sub, Inc., which will include a 1-for-50 reverse stock split. Additionally, the company's board has approved 2026 cash retention bonuses for key executives, including the CFO, CMO, and CEO, tied to specific financial and capital-raising milestones, replacing a regular bonus plan and salary increases. This decision comes after no bonuses were earned in 2025 due to unmet financial and business objectives.

SAN DIEGO, Nov. 21, 2025 ( GLOBE NEWSWIRE ) -- BioAtla, Inc. ( Nasdaq: BCAB ) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic ( CAB ) antibody therapeutics for the treatment of solid tumors, today announced that it has entered into ...

Image source: The Motley Fool.Thursday, November 13, 2025 at 4:30 p.m. ETNeed a quote from a Motley Fool analyst? Email pr@fool.comContinue reading ...

- Mec-V demonstrates median OS of 21.5 months in patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma compared with approximately 12 months with approved agents ...

BioAtla to Present Clinical Data for Mecbotamab Vedotin (BA3011) in Soft Tissue Sarcoma at ...

BioAtla ( NASDAQ:BCAB ) , a clinical-stage biotech developing therapies for hard-to-treat cancers, released its second quarter 2025 results on August 7, 2025. The company posted a net loss per share of $ ( 0.32 ) ( GAAP ) , improved from a $ ( 0.44 ) GAAP net loss per share in Q2 2024.

Adverse events were generally low-grade, transient, and readily manageable Achieved preliminary evidence of prolonged tumor control and tumor reductions in heavily pretreated adenocarcinoma patients Dose escalation now continuing at 1.2 mg weekly by subcutaneous flat dosing